athenahealth, Inc (ATHN) Shares Sold by Millennium Management LLC

Millennium Management LLC lessened its stake in athenahealth, Inc (NASDAQ:ATHN) by 62.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 81,952 shares of the health services provider’s stock after selling 136,652 shares during the period. Millennium Management LLC owned approximately 0.20% of athenahealth worth $10,903,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ATHN. The Manufacturers Life Insurance Company grew its position in athenahealth by 7.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,179 shares of the health services provider’s stock worth $166,000 after purchasing an additional 84 shares during the period. Principal Financial Group Inc. grew its position in athenahealth by 83.2% in the 3rd quarter. Principal Financial Group Inc. now owns 5,850 shares of the health services provider’s stock worth $728,000 after purchasing an additional 2,656 shares during the period. SG Americas Securities LLC bought a new stake in athenahealth in the 3rd quarter worth approximately $485,000. Legal & General Group Plc grew its position in athenahealth by 18.3% in the 3rd quarter. Legal & General Group Plc now owns 16,983 shares of the health services provider’s stock worth $2,112,000 after purchasing an additional 2,625 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its position in athenahealth by 7.6% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 183,984 shares of the health services provider’s stock worth $22,881,000 after purchasing an additional 13,006 shares during the period.

How to Become a New Pot Stock Millionaire

ATHN opened at $138.78 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.84 and a current ratio of 1.84. athenahealth, Inc has a fifty-two week low of $95.01 and a fifty-two week high of $158.66. The firm has a market cap of $5,564.80, a P/E ratio of 82.12, a PEG ratio of 2.90 and a beta of 1.13.

athenahealth (NASDAQ:ATHN) last released its earnings results on Thursday, February 1st. The health services provider reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.48. athenahealth had a net margin of 4.35% and a return on equity of 9.21%. The company had revenue of $329.20 million for the quarter, compared to analysts’ expectations of $319.64 million. During the same quarter in the previous year, the company earned $0.62 EPS. athenahealth’s revenue for the quarter was up 14.2% on a year-over-year basis. equities analysts expect that athenahealth, Inc will post 2.69 earnings per share for the current year.

In related news, CEO Jonathan Bush sold 25,000 shares of athenahealth stock in a transaction on Monday, February 5th. The shares were sold at an average price of $145.00, for a total transaction of $3,625,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jeffrey R. Immelt bought 7,200 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were purchased at an average price of $138.44 per share, for a total transaction of $996,768.00. Following the purchase, the director now owns 678 shares in the company, valued at approximately $93,862.32. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 47,555 shares of company stock worth $6,682,463. 3.20% of the stock is owned by corporate insiders.

A number of research firms have commented on ATHN. Bank of America began coverage on shares of athenahealth in a research report on Tuesday, February 27th. They issued a “neutral” rating and a $147.00 target price for the company. BidaskClub raised shares of athenahealth from a “strong sell” rating to a “sell” rating in a research report on Saturday, February 17th. Piper Jaffray reaffirmed a “buy” rating and issued a $160.00 target price on shares of athenahealth in a research report on Friday, February 16th. Royal Bank of Canada set a $141.00 target price on shares of athenahealth and gave the stock a “hold” rating in a research report on Thursday, February 15th. Finally, SunTrust Banks lifted their target price on shares of athenahealth to $180.00 and gave the stock a “buy” rating in a research report on Monday, February 5th. Three investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $144.35.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3340571/athenahealth-inc-athn-shares-sold-by-millennium-management-llc.html.

athenahealth Company Profile

athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.

Want to see what other hedge funds are holding ATHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for athenahealth, Inc (NASDAQ:ATHN).

Institutional Ownership by Quarter for athenahealth (NASDAQ:ATHN)

Receive News & Ratings for athenahealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Juno Therapeutics Inc  Receives $57.93 Average Target Price from Brokerages
Juno Therapeutics Inc Receives $57.93 Average Target Price from Brokerages
Lexicon Pharmaceuticals  Receives $25.67 Average Target Price from Analysts
Lexicon Pharmaceuticals Receives $25.67 Average Target Price from Analysts
PMC Commercial Trust  Earns Daily News Sentiment Rating of 0.27
PMC Commercial Trust Earns Daily News Sentiment Rating of 0.27
WideOpenWest  Earning Somewhat Favorable News Coverage, Analysis Finds
WideOpenWest Earning Somewhat Favorable News Coverage, Analysis Finds
Brokerages Set RingCentral  Target Price at $53.92
Brokerages Set RingCentral Target Price at $53.92
Comparing Kingstone Companies  & Its Competitors
Comparing Kingstone Companies & Its Competitors


Leave a Reply

© 2006-2018 Ticker Report. Google+.